🇺🇸 Octreotide LAR in United States

26 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 26

Most-reported reactions

1. Malignant Neoplasm Progression — 5 reports (19.23%)
2. Pain — 3 reports (11.54%)
3. Pituitary Tumour Benign — 3 reports (11.54%)
4. Weight Decreased — 3 reports (11.54%)
5. Abdominal Pain — 2 reports (7.69%)
6. Anorexia — 2 reports (7.69%)
7. Ascites — 2 reports (7.69%)
8. Death — 2 reports (7.69%)
9. Disease Progression — 2 reports (7.69%)
10. Drug Ineffective — 2 reports (7.69%)

Source database →

Frequently asked questions

Is Octreotide LAR approved in United States?

Octreotide LAR does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Octreotide LAR in United States?

Cedars-Sinai Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.